Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zogenix, Inc.
Commissioner Robert Califf’s comments offer further context for FDA’s unprecedented decision to reconvene an advisory committee for a second review of Amylyx’ AMX0035 for ALS.
Attorneys say the biggest step FDA could take to expand access to medication abortion would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.
Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
England’s health technology appraisal body NICE has recommended Galapagos’ Jyseleca for ulcerative colitis, Takeda’s Revestive for short bowel syndrome and Zogenix’s Fintepla for seizures associated with Dravet syndrome.
- Other Names / Subsidiaries
- Brabant Pharma, Modis Therapeutics, Inc. Zogenix International, Ltd. Zogenix Europe Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.